secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-06-18T21:00:18+00:00
Accession:  0001829126-26-006688
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc Technologies gets UAE IND approval for NEO212 brain cancer drug
---------------------------------------------------------------------

- Department of Health – Abu Dhabi granted IND status for NEO212, an oral perillyl alcohol-temozolomide conjugate.
- Phase 1 dose-escalation completed; 610 mg selected as recommended Phase 2 dose.
- Early signs of durable disease stabilization seen in recurrent glioblastoma and brain metastases.
- Company also submitted applications for NEO100 programs in UAE; awaiting decisions.
- UAE approval follows U.S. FDA discussions on potential registrational pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/0001829126-26-006688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626006688/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-006688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer